Enterprise Value

73.61M

Cash

74.14M

Avg Qtr Burn

-30.09M

Short % of Float

6.27%

Insider Ownership

21.78%

Institutional Own.

34.17%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IGALMI (dexmedetomidine) (BXCL501) Details
Mental health, Bipolar depression, Schizophrenia, Bipolar disease

Approved

Quarterly sales

BXCL501 Details
Mental health, Schizophrenia, Bipolar depression, Bipolar disease

Phase 3

Initiation

BXCL501 Details
Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease

Phase 3

Initiation

BXCL701 + KEYTRUDA Details
Neuroendocrine prostate cancer, Castration-resistant prostate cancer

Phase 2b

Update

BXCL701 + KEYTRUDA Details
Solid tumor/s, Cancer, Pancreatic cancer

Phase 2

Data readout

BXCL501 + Duloxetine Details
Major depressive disorder

Phase 2

Initiation

BXCL501 Details
Opioid use disorder

Phase 1

Update

BXCL501 Details
Mental health, Delirium, Agitation

Failed

Discontinued